Core Viewpoint - The antiviral oral liquid market is experiencing significant growth driven by the rising incidence of viral diseases and increasing health awareness among consumers, with a projected market size increase from 1.1 billion yuan in 2020 to 1.469 billion yuan in 2024, reflecting a compound annual growth rate of 7.5% [1][12]. Industry Overview - Antiviral oral liquids are common traditional Chinese medicine formulations, primarily composed of ingredients like Banlangen, Shigao, and Lugen, used for treating viral infections such as influenza and respiratory infections [3][5]. - The industry has evolved since the 1980s, transitioning from basic herbal formulations to more sophisticated products due to technological advancements, leading to improved efficacy and safety [5]. Market Dynamics - The demand for antiviral oral liquids is increasing due to the high prevalence of viral diseases and an aging population, alongside a shift in consumer perception of these products as essential for daily health protection [1][12]. - The rise of e-commerce platforms has further facilitated market growth by providing convenient access to these products [1][12]. Industry Chain - The industry chain consists of upstream raw material cultivation, production equipment, and packaging materials; midstream involves the manufacturing of antiviral oral liquids; and downstream includes sales through hospitals, pharmacies, clinics, and e-commerce platforms [8]. Competitive Landscape - The market is becoming increasingly competitive with numerous companies entering the field, necessitating continuous innovation and marketing efforts to stand out [13]. - Key players in the industry include ST Xiangxue, China Resources Sanjiu, Kangyuan Pharmaceutical, and others, each with unique product offerings and market strategies [1][13]. Development Trends - There is significant growth potential in the central and rural markets, where the penetration of antiviral oral liquids is currently low due to insufficient medical resources [21]. - Future innovations in nanotechnology and targeted drug delivery systems are expected to enhance product efficacy and reduce side effects, driving further advancements in the industry [22]. - The market is likely to see increased concentration as leading companies leverage technology and brand development to capture larger market shares, while new entrants may adopt innovative strategies to compete [23].
2025年中国ERP软件行业商业模式、产业链、发展历程、供需规模、市场结构及发展趋势研判:市场规模将增长至505.3亿元,制造领域占40.53%[图]